{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:16:25Z","timestamp":1788992185390,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ventilator-associated pneumonia (VAP) caries a morbidity and mortality risk in the preterm neonate, particularly in the context of rising global antimicrobial resistance driving infections due to multidrug-resistant Gram-negative bacteria. Cefiderocol, a siderophilic cephalosporin, has broad Gram-negative antimicrobial activity and central nervous system penetration and is used for the treatment of hospital-acquired pneumonia or VAP in adults. Scarce data exists on its use in neonates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case:<\/jats:title>\n            <jats:p>A female neonate born at 26\u2009+\u20096 weeks developed VAP at 21 days of life. She was commenced on corticosteroids, vancomycin and ceftazidime but continued to deteriorate. Sputum cultures yielded <jats:italic toggle=\"yes\">Stenotrophomonas maltophilia<\/jats:italic> resistant to trimethoprim\/sulfamethoxazole, ciprofloxacin and ceftazidime, with potential susceptibility to cefiderocol. Cerebrospinal fluid showed an elevated white cell count. In view of worsening respiratory and hemodynamic status, antibiotic treatment was changed to cefiderocol monotherapy at 30\u2009mg\/kg\/dose every 8 hours. Within 72 hours of commencing cefiderocol, the neonate was successfully extubated to variable-flow continuous positive airway pressure and showed ongoing clinical improvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Cefiderocol was integral for the care of our neonate without any immediate adverse safety consequences. We relied on dosing data from a conference abstract, due to the paucity of evidence on the use of novel antimicrobials. This lack of evidence is particularly concerning given preterm neonates are particularly vulnerable to infections with multidrug-resistant Gram-negative organisms due to their immature immune systems, prolonged hospital stay, repeated interventions and antimicrobial exposure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004051","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T20:04:08Z","timestamp":1690833848000},"page":"1012-1016","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Successful Use of Cefiderocol to Treat a Multidrug-resistant Stenotrophomonas maltophilia Ventilator-associated Pneumonia in an Extremely Preterm Neonate"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2567-8825","authenticated-orcid":false,"given":"Archana","family":"Koirala","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Nepean Hospital, Kingswood, New South Wales, Australia"},{"name":"National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia"},{"name":"School of Public Health, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia"},{"name":"Sydney Infectious Diseases Institute, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath","family":"Krishnappa","sequence":"additional","affiliation":[{"name":"Department of Neonatal Services, Nepean Hospital, Kingswood, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Banh","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nepean Hospital, Kingswood, New South Wales, Australia"},{"name":"Department of Microbiology, New South Wales Health Pathology, Kingswood, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Brandenburg","sequence":"additional","affiliation":[{"name":"Department of Neonatal Services, Nepean Hospital, Kingswood, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Findlay","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nepean Hospital, Kingswood, New South Wales, Australia"},{"name":"Department of Microbiology, New South Wales Health Pathology, Kingswood, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-0594","authenticated-orcid":false,"given":"Phoebe C. M.","family":"Williams","sequence":"additional","affiliation":[{"name":"National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia"},{"name":"School of Public Health, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia"},{"name":"Sydney Infectious Diseases Institute, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Infectious Diseases, Sydney Children Hospital, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"e1004179","DOI":"10.1371\/journal.pmed.1004179","article-title":"Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: a global neonatal sepsis observational cohort study (NeoOBS).","volume":"20","author":"Russell","year":"2023","journal-title":"PLoS Med"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41390-021-01745-7","article-title":"Neonatal multidrug-resistant Gram-negative infection: epidemiology, mechanisms of resistance, and management.","volume":"91","author":"Flannery","year":"2022","journal-title":"Pediatr Res"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/cid\/ciab010","article-title":"US FDA\u2019s assessment of the benefit-risk of cefiderocol for its initial complicated urinary tract infection indication.","volume":"73","author":"Echols","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00431-014-2278-6","article-title":"Risk factors for ventilator-associated pneumonia in the neonatal intensive care unit: a meta-analysis of observational studies.","volume":"173","author":"Tan","year":"2014","journal-title":"Eur J Pediatr"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000355539","article-title":"Ventilator-associated pneumonia in neonatal patients: an update.","volume":"105","author":"Cernada","year":"2013","journal-title":"Neonatology"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"e012298","DOI":"10.1136\/bmjopen-2016-012298","article-title":"Prevalence of Gram-negative bacteria in ventilator-associated pneumonia in neonatal intensive care units: a systematic review and meta-analysis protocol.","volume":"6","author":"Erfani","year":"2016","journal-title":"BMJ Open"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0049475517743360","article-title":"Stenotrophomonas maltophilia causing blood stream infection in neonates and infants: a cause for concern.","volume":"48","author":"Sah","year":"2018","journal-title":"Trop Doct"},{"key":"R10-20250614","article-title":"Stenotrophomonas maltophilia outbreak in neonatal intensive care unit and outbreak management.","volume":"9:147\u201352","author":"\u00c7etin","year":"2015","journal-title":"J Pediatr Infect Dis\/Cocuk Enfeksiyon Dergisi"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/01.ccm.0000510443.73051.e7","article-title":"Successful treatment of Stenotrophomonas maltophilia pneumonia is a preterm neonatal patient.","volume":"44","author":"Shah","year":"2016","journal-title":"Crit Care Med"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5005\/jp-journals-10071-23241","article-title":"Stenotrophomonas maltophilia: more than just a colonizer!.","volume":"23","author":"Baidya","year":"2019","journal-title":"Indian J Crit Care Med"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4212\/cjhp.v66i6.1305","article-title":"Trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia pneumonia in a neonate.","volume":"66","author":"Ryan","year":"2013","journal-title":"Can J Hosp Pharm"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.4076\/1752-1947-3-7389","article-title":"Successful treatment of Stenotrophomonas maltophilia meningitis in a preterm baby boy: a case report.","volume":"3","author":"Rojas","year":"2009","journal-title":"J Med Case Rep"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/1120009X.2017.1378834","article-title":"Surveillance of antimicrobial susceptibility patterns among Stenotrophomonas maltophilia isolated in China during the 10-year period of 2005-2014.","volume":"30","author":"Hu","year":"2018","journal-title":"J Chemother"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections.","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00431-002-1095-5","article-title":"Successful treatment of multi-resistant Stenotrophomonas maltophilia meningitis with ciprofloxacin in a pre-term infant.","volume":"161","author":"Lo","year":"2002","journal-title":"Eur J Pediatr"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00467-010-1473-6","article-title":"Treatment of Stenotrophomonas neonatal urinary tract infection with instillation of ciprofloxacin.","volume":"25","author":"Khassawneh","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.arcped.2012.01.011","article-title":"Neonatal infection with Stenotrophomonas maltophilia (2 case studies).","volume":"19","author":"Issaoui","year":"2012","journal-title":"Arch Pediatr"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014 Study).","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41564-021-00870-7","article-title":"Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries.","volume":"6","author":"Sands","year":"2021","journal-title":"Nat Microbiol"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2471\/BLT.22.288623","article-title":"Antibiotics needed to treat multidrug-resistant infections in neonates.","volume":"100","author":"Williams","year":"2022","journal-title":"Bull World Health Organ"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria.","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin.","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40121-020-00286-6","article-title":"Cefiderocol: a novel agent for the management of multidrug-resistant Gram-negative organisms.","volume":"9","author":"Wu","year":"2020","journal-title":"Infect Dis Ther"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"e01872-19","DOI":"10.1128\/AAC.01872-19","article-title":"Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae in a pediatric patient.","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jgar.2021.04.025","article-title":"Compassionate use of cefiderocol for VIM metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa infection in a toddler with Burkitt lymphoma.","volume":"26","author":"Grasa","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12098-022-04468-7","article-title":"Cefiderocol as salvage therapy for carbapenem-resistant Klebsiella pneumoniae sepsis in an extremely preterm neonate.","volume":"90","author":"Bawankule","year":"2023","journal-title":"Indian J Pediatr"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40121-022-00735-4","article-title":"Bloodstream infection due to a VIM-metallo-\u03b2-lactamase-producing Klebsiella pneumoniae treated with cefiderocol in a preterm newborn.","volume":"12","author":"Monari","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/phar.2187","article-title":"Pharmacokinetics of the meropenem component of meropenem-vaborbactam in the treatment of KPC-producing Klebsiella pneumoniae bloodstream infection in a pediatric patient.","volume":"38","author":"Hanretty","year":"2018","journal-title":"Pharmacotherapy"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.","volume":"55","author":"Gainey","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","article-title":"Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections.","volume":"73","author":"Warner","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:03:01Z","timestamp":1749945781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004051","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,24]]}}}